Vaccine clinical trial

AERAS-404

Status: Study completed
Number of volunteers: 70
​​​​​​​Number of visits: 12

A Phase I Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of BCG and AERAS-404 Administered as a Prime-Boost Regimen to HIV-Negative, TB-Negative, BCG-Naive Adults

​​​​​​​BCG is currently the only licensed vaccine for the prevention of tuberculosis. The incomplete protection of this vaccine, especially in adults, makes it necessary to develop an effective booster in order to increase protection from TB disease.

The aim of this study is to assess the safety and the efficiency of BCG and a AERAS-404 two- or three-dose boost regimen administrated to healthy adults. 70 volunteers will be enrolled at the vaccine and immunotherapy Center, CHUV (Beaumont Hospital) for 10 months.For this study, we have recruited 18-50 years old women and men in good health and who didn’t get BCG vaccination.

​​​​​​​For further information on this study, please contact us by phone +41 21 314 1160 / +41 21 314 1163.

PCAN001

Status: Study completed
Number of volonteers: 24 (2 groups of 12 volunteers)
Number of visits: 13 or 15 (depending on the group number)

A Phase I randomized placebo-controlled study of a virosome-formulated anti-Candida vaccine (PEV7) administered by the vaginal or intramuscular route to healthy adult volunteers

​​​​​​​The aim of PCAN001 study is to develop a preventive vaccine against the yeast Candida in order to treat and prevent the vaginal infections due to Candida albicans (vaginal mycosis).

Two objectives have been defined for this study: the first one is the evaluation of the safety and the tolerability of the vaccine and the second one is the determination of the immune response induced by this vaccine. Two types of immunisation ways will be tested and compared (intramuscular injections or intravaginal administration) over a period of 15 months.

For this study, we have recruited 18-45 years old women in good health and under oral contraceptive (pill). For further information on this study, please contact us by phone +41 21 314 1160 / +41 21 314 1163.

Seasonal flu

Status: Study completed
Number of volunteers: 40
​​​​​​​Lenght of the study: 1
month

​​​​​​​Study of the immune response to vaccination against seasonal flu in different groups of age

​​​​​​​The aim of this study is to compare and to assess the effect of aging on the immune system, in the context of the vaccination against seasonal flu.40 healthy volunteers, men and women, aged 45-65 years old will be enrolled in this study for 1 month. A total of 5 visits are scheduled including a short check-up, one baseline visit (of note: for CHUV employees, the vaccination could be performed at the health care medicine) and 3 follow-up visits including blood samples.

If you plan to get vaccinated against flu and you are 20-65 years old, you could be interested by this study!

For further information on this study, please contact us by phone +41 21 314 1160 / +41 21 314 1163.

Contact

Division of Immunology and Allergy
Monday to Friday: 8 am - 6 pm
Vaccine and Immunotherapy Center
1011 Lausanne, Suisse
Tél. +41 21 314 1160
Tél. +41 21 314 1163
Fax +41 21 314 1161
 Dernière mise à jour le 28/06/2019 à 08:09